Can a shorter chemo schedule work as well for head and neck cancer?
NCT ID NCT07419464
First seen Feb 19, 2026
Summary
This study compares two ways of giving the chemotherapy drug 5-FU to people with head and neck cancer that has spread or come back after prior treatments. One group gets the drug over two days every two weeks, the other over four days every three weeks. The goal is to see which schedule better controls the cancer while causing fewer side effects. About 46 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
5-Fluorouracil (5-FU), a chemotherapy drug
What this could lead to
If successful, this trial could identify a better-tolerated dosing schedule of 5-FU that still controls tumor growth in patients with advanced head and neck cancer.
What could go wrong
This is a small, early-phase trial (46 participants) testing two existing regimens, not a new drug. The expected response rate is modest (10% or higher), and side effects like dose reductions or delays are common with chemotherapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.